Breast size in relation to endogenous hormone levels, body constitution, and oral contraceptive use in healthy nulligravid women aged 19-25 years

American Journal of Epidemiology

Volumn 145, Issue 7, 1997, Pages 571-580

  Jernström, Helena ^a   Olsson, Håkan ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

body constitution; breast; contraceptives; estradiol; hormones; insulin like growth factor I; oral; sex hormone binding globulin; women

Indexed keywords

CYPROTERONE ACETATE; DESOGESTREL; ESTRADIOL; FOLLITROPIN; GESTODENE; LEVONORGESTREL; LUTEINIZING HORMONE; LYNESTRENOL; NORETHISTERONE; ORAL CONTRACEPTIVE AGENT; PROGESTERONE; PROLACTIN; SEX HORMONE BINDING GLOBULIN; SOMATOMEDIN C; TESTOSTERONE;

ADULT; ARTICLE; BODY DISTRIBUTION; BODY MASS; BREAST CARCINOMA; FEMALE; FOLLICULAR PHASE; HORMONE BLOOD LEVEL; HUMAN; LUTEAL PHASE; MAJOR CLINICAL STUDY; NULLIPARA; ORAL CONTRACEPTION; ORGAN SIZE; PREGNANCY;

EID: 1842366676     PISSN: 00029262     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.aje.a009153     Document Type: Article

References (35)

1. MacMahon B, Cole P, Lin TM, et al. Age at first birth and breast cancer risk. Bull World Health Organ 1970;43:209-21.
2. Kelsey JL, Gammon MD, John EM. Reproductive factors and breast cancer. Epidemiol Rev 1993; 15:36-47.
3. Russo J, Tay LK, Russo IH. Differentiation of the mammary gland and susceptibility to carcinogenesis. Breast Cancer Res Treat 1982;2:5-73.
4. Preston-Martin S, Pike MC, Ross RK, et al. Increased cell division as a cause of human cancer. Cancer Res 1990;50: 7415-21.
5. Anderson TJ, Battersby S, King RJ, et al. Oral contraceptive use influences resting breast proliferation. Hum Pathol 1989; 20:1139-44.
6. Potten CS, Watson RJ, Williams GT, et al. The effect of age and menstrual cycle upon proliferative activity of the normal human breast. Br J Cancer 1988;58:163-70.
7. Olsson H, Jernström H, Alm A, et al. Proliferation of the breast epithelium in relation to menstrual cycle phase, hormonal use and reproductive factors. Breast Cancer Res Treat 1996:40:187-96.
8. Pike MC, Spicer DV, Dahmoush L, et al. Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. Epidemiol Rev 1993;15:17-35.
9. Olsson H, Möller TR, Ranstam J. Early oral contraceptive use and breast cancer among premenopausal women: final report from a study in southern Sweden. J Natl Cancer Inst 1989;81: 1000-4.
10. Pike MC, Henderson BE, Casagrande JT, et al. Oral contraceptive use and early abortion as risk factors for breast cancer in young women. Br J Cancer 1981;43:72-6.
11. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53,297 women with breast cancer and 100,239 women without breast cancer from 54 epidemiological studies. Lancet 1996;347:1713-27.
12. Dickson R. Biochemical control of breast development. In: Harris J, Lippman M, Morrow M, et al, eds. Diseases of the breast. Philadelphia, PA: Lippincott-Raven, 1996:15-25.
13. Olsson H. Risk for malignant tumors after oral contraceptive use: Is it related to organ size while taking the Pill? Med Oncol Tumor Pharmacother 1990;7:61-4.
14. Hoe AL, Mullee MA, Royle GT, et al. Breast size and prognosis in early breast cancer. Ann R Coll Surg Engl 1993;75: 18-22.
15. Beijerinck D, van Noord PA, Kemmeren JM, et al. Breast size as a determinant of breast cancer. Int J Obes Relat Metab Disord 1995;19:202-5.
16. Thurfjell E, Hsieh CC, Lipworth L, et al. Breast size and mammographic pattern in relation to breast cancer risk. Eur J Cancer Prev 1996;5:37-41.
17. Bernstein L, Ross RK. Endogenous hormones and breast cancer risk. Epidemiol Rev 1993;15:48-65.
18. Bruning PF, Van Doom J, Bonfrèr JM, et al. Insulin-like growth-factor-binding protein 3 is decreased in early-stage operable pre-menopausal breast cancer. Int J Cancer 1995;62: 266-70.
19. Thomas DB. Do hormones cause breast cancer? Cancer 1984; 53(suppl):595-604.
20. Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocrinol Rev 1995; 16: 3-34.
21. Underwood L, van Wyk J. Normal and aberrant growth. In: Wilson J, Foster D, eds. Williams' textbook of endocrinology. 8th ed. Philadelphia, PA: WB Saunders, 1992:1079-138.
22. Wang D. Prolactin and its role in the clinical course and risk of human breast cancer. Rev Endocr Relat Cancer 1993;45: 25-39.
23. Ferguson DJ, Anderson TJ. Morphological evaluation of cell turnover in relation to the menstrual cycle in the "resting" human breast. Br J Cancer 1981;44:177-81.
24. Jernström H, Knutsson M, Olsson H. Temporary increase of FSH levels in healthy, nulliparous, young women after cessation of low-dose oral contraceptive use. Contraception 1995; 52:51-6.
25. Nilsson B, von Schoultz B. Binding of levonorgestrel, norethisterone and desogestrel to human sex hormone binding globulin and influence on free testosterone levels. Gynecol Obstet Invest 1989;27:151-4.
26. Jernström H, Olsson H. Suppression of plasma insulin-like growth factor-1 levels in healthy, nulliparous, young women using low dose oral contraceptives, Gynecol Obstet Invest 1994;38:261-5.
27. Kuhl H, Jung-Hoffmann C, Weber J, et al. The effect of a biphasic desogestrel-containing oral contraceptive on carbohydrate metabolism and various hormonal parameters. Contraception 1993;47:55-68.
28. Murphy A, Cropp CS, Smith BS, et al. Effect of low-dose oral contraceptive on gonadotropins, androgens, and sex hormone binding globulin in nonhirsute women. Fertil Steril 1990;53: 35-9.
29. Söderqvist G, Olsson H, Wilking N, et al. Metabolism of estrone sulfate by normal breast tissue: influence of menopausal status and oral contraceptives. J Steroid Biochem Mol Biol 1994;48:221-4.
30. Jernström H, Knutsson M, Taskila P, et al. Plasma prolactin in relation to menstrual cycle phase, oral contraceptive use, arousal time and smoking habits. Contraception 1992;46: 543-8.
31. Kato I, Beinart C, Bleich A, et al. A nested case-control study of mammographic patterns, breast volume, and breast cancer (New York City, NY, United States). Cancer Causes Control 1995;6:431-8.
32. Fowler PA, Casey CE, Cameron GG, et al. Cyclic changes in composition and volume of the breast during the menstrual cycle, measured by magnetic resonance imaging. Br J Obstet Gynaecol 1990;97:595-602.
33. Milligan D, Drife JO, Short RV. Changes in breast volume during normal menstrual cycle and after oral contraceptives. Br Med J 1975;4:494-6.
34. Williams G, Anderson E, Howell A, et al. Oral contraceptive (OCP) use increases proliferation and decreases oestrogen receptor content of epithelial cells in the normal human breast. Int J Cancer 1991;48:206-10.
35. Olsson H. Reproductive and hormonal factors in relation to cancer occurrence in the breast, prostate, testis, uterine corpus, ovary, uterine cervix, and thyroid gland. In: Macieira-Coelho A, Nordenskjöld B, eds. Cancer and aging. Boston, MA: CRC Press, 1990:109-26.